Clinical Trials | June 03, 2026
Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
Seasoned HR leader brings over 15 years of experience in global talent strategy, organizational transformation, and workforce planning
Vijay brings more than 28 years of experience across healthcare, technology, edtech, manufacturing, and global business environments
The therapy also delivered significant improvements in key liver enzyme markers
World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
